
Myxoid liposarcoma: it's a hippo's world
Author(s) -
Regina Carla,
Hettmer Simone
Publication year - 2019
Publication title -
embo molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.923
H-Index - 107
eISSN - 1757-4684
pISSN - 1757-4676
DOI - 10.15252/emmm.201910470
Subject(s) - liposarcoma , hippo signaling pathway , medicine , cancer research , pathology , sarcoma , biology , microbiology and biotechnology , signal transduction
Fused in sarcoma: DNA damage‐inducible transcript 3 protein ( FUS : DDIT 3) is a chimeric fusion oncoprotein present in 90% of human myxoid liposarcomas ( MLS ). The study by Trautmann et al in this issue of EMBO Molecular Medicine utilizes a drop‐out RNA i screen to establish hyperactive Yes‐associated protein 1 ( YAP 1), a major downstream nuclear effector of the Hippo signaling pathway, as a selectively essential transcript promoting viability and growth of MLS . These observations add to a growing body of evidence underscoring the importance of dysregulation of Hippo signaling in soft‐tissue sarcomas expressing fusion oncoproteins and identify a novel target for therapeutic intervention in MLS . Comprehensive molecular characterization pipelines are needed to screen patients with advanced soft‐tissue sarcomas for the presence of druggable alterations, including but not limited to nuclear YAP 1 expression in MLS , to facilitate treatment decisions and advance therapy.